Inactive Instrument

Dishman Carbogen Amcis Ltd Stock NSE India S.E.

Equities

Pharmaceuticals

End-of-day quote NSE India S.E.
- INR - Intraday chart for Dishman Carbogen Amcis Ltd
Sales 2022 21.41B 257M Sales 2023 24.13B 289M Capitalization 19.56B 235M
Net income 2022 180M 2.16M Net income 2023 -298M -3.57M EV / Sales 2022 2.02 x
Net Debt 2022 14.27B 171M Net Debt 2023 19B 228M EV / Sales 2023 1.6 x
P/E ratio 2022
161 x
P/E ratio 2023
-65.6 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 29.93%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 38 12-04-06
Director of Finance/CFO 42 -
Chief Operating Officer - -
Members of the board TitleAgeSince
Chairman 73 07-03-16
Director/Board Member 73 17-03-16
Director/Board Member 76 17-03-16
More insiders
Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, and disinfectants. The Company’s segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. Its Marketable Molecules segment manufactures and supplies intermediates, chemicals, and various products for pharmaceutical, cosmetic and related industries. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd. and Dishman Carbogen Amcis (Singapore) Pte. Ltd.
More about the company